May 4, 2019

Giving up revenue to help opioid victims

       In addition to dubious sexual abuse investigations, another of O'Melveny's revenue generators is a massive multi-state opiate addiction case. Another firm defending such cases recently started a public campaign to settle the matter, to "get the monies to the communities that need them, to the people that are addicted ... rather than to pay attorneys’ fees for years and years and years to come.

       I don't think you will ever see such a campaign by O'Melveny. In fact, O'Melveny just reportedly "trash[ed]" the victims' complaint. O'Melveny's partners valued money far too much to think of giving up revenue. They seemed like the type to milk every last dollar out of whatever they could get their hands on.

       [Addendum: Here is O'Melveny's chair, Brad Butwin, boasting about the money his firm made on the Oklahoma opioid trial, as well as the money he expects to make on future opioid trials.]
Johnson & Johnson, Michael Ullmann Executive Vice President and General Counsel, J&J, Janssen Pharmaceutica, opioid, opiate lawsuit, omm